Combination Therapy with Venetoclax for Patients With Chronic Lymphocytic Leukemia

In May 2019, the Food and Drug Administration (FDA) approved venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). According to Milos Miljković, M.D., who studies Chronic Lymphocytic Leukemia in NCI’s Center for Cancer Research, “This is the 2’nd chemotherapy-free […]